Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous stem cell therapy in Multiple System Atrophy
NCT07465198Phase 2Not yet recruiting
- Sponsor
- Biocells Medical
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of neuroinduced mesenchymal stem cells in multiple system atrophy (MSA), sponsored by Biocells Medical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
neuroinduced mesenchymal stem cells
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT07465198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07465198.